Improved glucose tolerance in zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

Diabetes

Volumn 47, Issue 8, 1998, Pages 1253-1258

  Pederson, Raymond A ^a   White, Heather A ^a   Schlenzig, Dagmar ^b   Pauly, Robert P ^a   McIntosh, Christopher H S ^a   Demuth, Hans Ulrich ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HANS KNÖLL INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; GLUCAGON LIKE PEPTIDE 1; INSULIN; ISOLEUCINE THIAZOLIDIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DESORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; MASS SPECTROMETRY; NONHUMAN; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT;

EID: 0031870418     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.47.8.1253     Document Type: Article

References (29)

1. Unger RH, Eisentraut AM: Entero-insular axis. Arch Intern Med 123:261-266, 1969
2. Pederson RA: GIP In Gut Peptides. Walsh J, Dockray G, Eds. New York, Raven, p. 217
3. Habener JF: The incretin concept and its relevance to diabetes. Endocrinol Metab Clin North Am 22:775-794, 1993
4. Holst JJ: Enteroglucagon. In Annual Review of Physiology. 1997, p. 257-271
5. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1(7-36), and peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
6. Kieffer TJ, McIntosh CHS, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
7. Deacon CF, Johnsen AH, Hoist JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
8. Pauly RP, Rosche F, Wermann M, McIntosh CHS, Pederson RA, Demuth H-U: Investigation of glucose-dependent insulinotropic polypeptide (1-42) and glucagon-like peptide-1 (7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization time of flight mass spectrometry. J Biol Chem 271:23222-23229, 1996
9. Demuth H-U, Heins J: Catalytic mechanism of dipeptidyl peptidase IV. In Dipeptidyl Peptidase IV (CD 26) in Metabolism and the Immune Response. Fleischer B, Ed. Georgetown. R.G. Landes Biochemical Publishers, 1995. p. 1-37
10. Schmidt WE, Siegel EG, Ebert R, Creutzfeldt W: N-terminal tyrosine-alanine is required for the insulin-releasing activity of glucose-dependent insulinotropic polypeptide (GIP) (Abstract). Eur J Clin Invest 16:A9, 1986
11. Brown JC, Dahl M, McIntosh CHS, Otte SC, Pederson RA: Actions of GIP Peptides 2:241-245, 1981
12. Suzuki S, Kawai K, Ohashi S, Mukai H, Yamashita K: Comparison of the effects of various C-terminal and N-terminal fragment poptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology 125:3109-3114, 1989
13. Gefel D, Hendrick GK, Mojsov S, Habener J, Weir GC: Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3′,5′-monophosphate formation. Endocrinology 126:2164-2168, 1990
14. Rahfeld J, Schieshorn M, Hantredt B, Neubert K, Heins J: Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates for dipeptidyl peptidase IV? Biochem Biophys Acta 1076:314-316, 1991
15. Schön E, Born I, Demuth H-U, Faust J, Neubert K, Steinmetz T, Barth A, Ansorge S: Dipeptidyl peptidase IV in the immune system: effect of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol Chem Hoppe-Seyler 372:305-311, 1991
16. Ionescu E, Santor FJ, Jeanrenaud B: Abnormal oral glucose tolerance in genetically obese (fa/fa) rats. Am J Physiol E500-E506, 1985
17. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15:318-368, 1992
18. Nauck MA, Hoist JJ, Willms B: Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Melab Res 29:411-416, 1997
19. Pederson RA, Buchan AMJ, Sahedi-Asl S, Chan CB, Brown JC: Effect of jejunoileal bypass in the rat on the enteroinsular axis. Regul Pept 5:53-63, 1982
20. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habner JF: Insulinotropic action of glucagon-like peptide-1 (7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
21. Nauck MA, Kleine N, Ørskov C, Hoist JJ, Willms B, Creutzfeldt W: Normal- ization of fasting hyperglycemia by exogenous glucagon-like peptide-1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:441-444, 1993
22. Chan CB, Pederson RA, Buchan AMJ, Tubesing KB, Brown JC: Gastric inhibitory polypeptide (GIP) and hyperinsulinemia in the Zucker (fo/fa) rat. Diabetes 33:536-542, 1984
23. Jia X, Elliott R, Kwok YN, Pederson RA, McIntosh CHS: Altered glucose-dependence of glucagon-like peptide-I (7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas. Diabetes 44:495-500, 1995
24. Orskov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptide-1 (proglucagon 78-107 amide) on endocrine secretion from the pig pancreas, antrum, and stomach. Endocrinology 123:2009-2013, 1988
25. Creutzfeldt W, Kleine N, Willms B, Orskov C, Holst JJ, Nauck M: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide-1 (7-36) amide in type 1 diabetic patients. Diabetes Care 19:580-586, 1996
26. D'Alessio DA, Kalm SE, Leusner CR, Ensinck JW: Glucagon-like peptide enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266, 1994
27. D'Alessio DA, Prigeon RL, Ensinck JW: Enterai enhancement of glucose disposition by both insulin-dependent and insulin-independent processes: a physiological role of glucagon-like peptide-1. Diabetes 44:1433-1437, 1995
28. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 72-107 amide) inhibits gastric and pancreatic functions in man. Digest Dis Sci 38:665-673, 1993
29. Rohner-Jeanrenaud F, Jeanrenaud B: Abnormal regulation of pancreatic glucagon secretion in obese fa/fa rats. Diabetologia 31:235-240, 1988